reports
Molecular Partners Publishes Invitation to Annual General Meeting 2026...
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today published the invitation to the Annual General Meeting 2026 and announced the nomination of Clare Fisher for election as a new member of the Board of Directors (BoD) at the Annual...
Molecular Partners Presents New Preclinical Data Highlighting Radio-DA...
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes 177Lu or 203Pb allows for rapid expansion of pipeline with multiple therapeutic isotopes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it wi...
Molecular Partners to Hold Three Poster Presentations at AACR 2026
Molecular Partners to Hold Three Poster Presentations at AACR 2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present three posters at the American Association for Cancer Research (AACR) 2026 Annual Meeting, taking place April 17-22 in San Diego, California, USA. Details of the presentations at AACR 2026: Logic-gated Switch-DARPin T cel...
Molecular Partners Reports Highlights and Financial Results for Full Y...
Molecular Partners Reports Highlights and Financial Results for Full Year 2025 Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data anticipated in 2026Second Radio-DARPin MP0726 targeting MSLN progressing towards first-in-human imaging; nomination of new Radio-DARPin candidates anticipated mid-2026Development agreement signed with leading radio-isotope specialist Eckert & Ziegler, enabling proprietary Radio-DARPin candidates with range of isotopes, incl...
Molecular Partners Signs Development Agreement with Eckert & Ziegler f...
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced ...
Molecular Partners Announces Participation in March Investor Conferenc...
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences. Molecular Partners will also issue its full-year 2025 financial report, along with its Annual Report, on March 12, 2026. Details o...
Molecular Partners Announces Presentation of First Imaging and Dosimet...
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine exper...
Molecular Partners Highlights Clinical Development Progress and Antici...
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026Phase 2 investigator-initiated trial of MP0317 now open with patient dosing ongoing, exploring MP0317 in combination with standard-of-care for patients with cholangiocarcinomaPhase 1/2a trial of multi-specific T cell engager MP0533 on...
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Co...
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present the Company’s latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15 in San Francisco, CA, USA. Chief Executive Officer Patrick Amstutz will pres...
Molecular Partners Forms Scientific Advisory Board to Accelerate Devel...
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant clinical and industry expertise, supporting transition from early clinical validation to strategic development ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drug...
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial...
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant...
Molecular Partners AG: 1 director
A director at Molecular Partners AG sold 35,000 shares at 0.000CHF and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy M...
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2026 Molecular Partners to host confer...
Molecular Partners presents additional preclinical proof-of-concept da...
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing tumor-associated antigens MSLN and EpCAM Induced significant tumor regression in vivo without causing systemic cytokine release, indicating favorable safety profile ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcem...
Molecular Partners to present updated data from Phase 1/2a trial of MP...
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present updated data from a Phase 1/2a trial of MP0533, a novel, multispecific T cell engager for acute myeloid leukemia (AML) patients, in a poster at t...
Molecular Partners Reports Q3 2025 Financial Results and Clinical Prog...
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images from MP0712 compassionate care program to be presented at TRP in November; additional programs planned for 2026, including MP0726 targeting mesothelin. Updated data from Phase 1/2a trial of MP0533, a multispecific T cell engager for AML, to be presen...
Molecular Partners reports financial results and highlights recent cli...
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025 MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025IND filing on first radio-DARPin program MP0712 and initiation of Phase 1 trial expected by end 2025; update on early imaging work planned in Q4 2025; expanded strategic radiotherapy partnership with Orano MedAppointed Martin Steegmaier, Ph.D. as CSO and member of Executive ...
Molecular Partners appoints Martin Steegmaier as Chief Scientific Offi...
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced t...
Molecular Partners and Orano Med present preclinical data on mesotheli...
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano MedPromising tumor accumulation and attractive biodistribution shown in vivo, selective binding to membrane-bound MSLN with positive tumor to kidney ratio ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 22, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 ...
Molecular Partners presents positive data from ongoing Phase 1/2a tria...
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 monthsAcceptable safety profile across all cohorts, including in cohort 8 with steeper step-up dosingData support further dose optimization to maximize therapeutic benefit of MP0533, with dosing in cohort 9 now ongoing ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR AG ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.